Toll-like receptors (TLrs) have frst been characterized for their capacity to detect conserved microbial components like lipopolysaccharide (LPS) and double-stranded rNA, resulting in the elicitation of potent (innate) immune responses against invading pathogens. More recently, TLrs have also been shown to promote the activation of the cognate immune system against cancer cells. Today, only three TLr agonists are approved by FDA for use in humans: the bacillus Calmette-Guérin (BCG), monophosphoryl lipid A (MPL) and imiquimod. BCG (an attenuated strain of Mycobacterium bovis) is mainly used as a vaccine against tuberculosis, but also for the immunotherapy of in situ bladder carcinoma. MPL (derived from the LPS of Salmonella minnesota) is included in the formulation of Cervarix®, a vaccine against human papillomavirus-16 and -18. imiquimod (a synthetic imidazoquinoline) is routinely employed for actinic keratosis, superfcial basal cell carcinoma, and external genital warts (condylomata acuminata). in this Trial watch, we will summarize the results of recently completed clinical trials and discuss the progress of ongoing studies that have evaluated/are evaluating FDA-approved TLr agonists as of-label medications for cancer therapy.
|Nummer van het tijdschrift||6|
|Status||Gepubliceerd - 2012|